Market Overview:
The global genetic COPD market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The market growth can be attributed to the increasing prevalence of COPD, growing awareness about genetic testing for COPD, and technological advancements in the field of genetic testing. However, factors such as high cost of genetic tests and lack of reimbursement policies are restraining the growth of this market. The global Genetic COPD Market is segmented on the basis of type, application, and region. On the basis of type, it is divided into Global Genetic COPD Market Size Growth Rate by Indication: 2016 VS 2021 VS 2027 (Augmentation Therapy, Cystic Fibrosis(CF), Non-CF Bronchiectasis(NCFB), Other). By application, it is classified into Hospitals, Specialty Clinics Pharmacies Others) hospitals held a dominant share in 2017 owing to rising numberof hospital admissions for diagnosis and treatmentof respiratory diseases.
Product Definition:
Genetic COPD is a type of COPD that is passed down in families. It can cause problems with breathing and make it difficult to exercise. Genetic COPD is important because it can help doctors understand why some people develop COPD and others do not.
Global Genetic COPD Market Size Growth Rate by Indication: 2016 VS 2021 VS 2027:
Global genetic COPD market was valued at USD 6.7 billion in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 7.0% from 2021 to 2027. The increasing prevalence of Chronic Obstructive Pulmonary Disease (COPD), rising geriatric population, growing awareness about the available treatment options, and technological advancements are some major factors driving the global genetic COPD market growth over the forecast period.
Augmentation Therapy:
Augmentation therapy is a procedure done to increase the size or strength of the lungs. It’s used in genetic COPD and it works by making new airway passage ways which are larger than normal. The treatment is mainly done with surgery but there are also medicines that can be taken as supplements to help lung function along with medication for severe cases.
Application Insights:
The others segment held the largest share of genetic COPD market in 2017. This segment includes alpha 1-antitrypsin deficiency, cystic fibrosis, and non-CF bronchiectasis. The application of genetic COPD therapies is expected to witness significant growth over the forecast period owing to increasing awareness about these conditions and growing acceptance for advanced therapy options among patients suffering from this condition.
Specialty clinics are anticipated to register the fastest CAGR in terms of revenue during the forecast period due to an increase in demand for personalized medicine that targets specific genes responsible for causing disease symptoms. In addition, a rise in prevalence rates coupled with high treatment costs is expected to boost demand over the coming years.
Regional Analysis:
North America dominated the global market in 2018. The presence of well-developed healthcare infrastructure, high awareness levels pertaining to the available treatment options, and favorable reimbursement policies are some factors attributing to its large share. In addition, a rise in prevalence of genetic COPD is also expected to contribute towards its growth over the forecast period.
Asia Pacific is estimated to be the fastest-growing regional market from 2018 to 2030 owing with growing patient pool and increasing government initiatives for early diagnosis & treatment of chronic lung diseases such as asthma and CF. Moreover, rising disposable income levels will also boost demand for COPD drugs in this region over the forecast period due to changing lifestyle habits amongst consumers which results into an increased risk of developing respiratory disorders such as bronchitis & emphysema or asthma among others (Spiraling Demand For Asthma And Bronchitis Drugs).
Growth Factors:
- Increasing prevalence of COPD: The global prevalence of COPD is expected to increase from approximately 210 million in 2015 to nearly 250 million by 2025. This is due to the aging population and increasing exposure to risk factors such as smoking and air pollution.
- Advances in genetic sequencing technology: The development of next-generation sequencing (NGS) technologies has led to a decline in the cost of genetic sequencing, making it more accessible for clinical use. This has allowed for the identification of new gene variants associated with COPD, providing new targets for drug development.
- Growing interest in precision medicine: There is growing interest in precision medicine, which involves using genomic information to tailor treatment decisions based on an individual’s unique genetic profile. Precision medicine could play a role in the diagnosis and treatment of COPD, particularly for patients with rare gene variants that are not currently targeted by therapies.
- Development of novel therapies: Several novel therapies are currently being developed for the treatment of COPD, including drugs that target specific gene variants or proteins involved in the pathogenesis of the disease. These therapies could provide relief from symptoms and improve quality of life for patients with COPD .
Scope Of The Report
Report Attributes
Report Details
Report Title
Genetic COPD Market Research Report
By Type
Global Genetic COPD Market Size Growth Rate by Indication: 2016 VS 2021 VS 2027, Augmentation Therapy, Cystic Fibrosis(CF), Non-CF Bronchiectasis(NCFB), Other
By Application
Hospitals, Specialty Clinics, Pharmacies, Others
By Companies
Pfizer, Baxter, AstraZeneca, Grifols, Teva Pharmaceutical Industries, Boehringer Ingelheim, Kamada Ltd, GlaxoSmithKline, CSL Behring, Takeda, LFB Biomedicaments, Abeona Therapeutics, Biogen, Vertex Pharmaceuticals, Baxalta, Arrowhead Research Corporation, ProBioGen, Chiesi Pharmaceuticals, Kedrion Group, ProMetic Life Sciences
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
135
Number of Tables & Figures
95
Customization Available
Yes, the report can be customized as per your need.
Global Genetic COPD Market Report Segments:
The global Genetic COPD market is segmented on the basis of:
Types
Global Genetic COPD Market Size Growth Rate by Indication: 2016 VS 2021 VS 2027, Augmentation Therapy, Cystic Fibrosis(CF), Non-CF Bronchiectasis(NCFB), Other
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Specialty Clinics, Pharmacies, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Pfizer
- Baxter
- AstraZeneca
- Grifols
- Teva Pharmaceutical Industries
- Boehringer Ingelheim
- Kamada Ltd
- GlaxoSmithKline
- CSL Behring
- Takeda
- LFB Biomedicaments
- Abeona Therapeutics
- Biogen
- Vertex Pharmaceuticals
- Baxalta
- Arrowhead Research Corporation
- ProBioGen
- Chiesi Pharmaceuticals
- Kedrion Group
- ProMetic Life Sciences
Highlights of The Genetic COPD Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Global Genetic COPD Market Size Growth Rate by Indication: 2016 VS 2021 VS 2027
- Augmentation Therapy
- Cystic Fibrosis(CF)
- Non-CF Bronchiectasis(NCFB)
- Other
- By Application:
- Hospitals
- Specialty Clinics
- Pharmacies
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Genetic COPD Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Genetic COPD is a term used to describe a form of COPD that is caused by an inherited gene.
Some of the key players operating in the genetic copd market are Pfizer, Baxter, AstraZeneca, Grifols, Teva Pharmaceutical Industries, Boehringer Ingelheim, Kamada Ltd, GlaxoSmithKline, CSL Behring, Takeda, LFB Biomedicaments, Abeona Therapeutics, Biogen, Vertex Pharmaceuticals, Baxalta, Arrowhead Research Corporation, ProBioGen, Chiesi Pharmaceuticals, Kedrion Group, ProMetic Life Sciences.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Genetic COPD Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Genetic COPD Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Genetic COPD Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Genetic COPD Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Genetic COPD Market Size & Forecast, 2018-2028
4.5.1 Genetic COPD Market Size and Y-o-Y Growth
4.5.2 Genetic COPD Market Absolute $ Opportunity
Chapter 5 Global Genetic COPD Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Genetic COPD Market Size Forecast by Type
5.2.1 Global Genetic COPD Market Size Growth Rate by Indication: 2016 VS 2021 VS 2027
5.2.2 Augmentation Therapy
5.2.3 Cystic Fibrosis(CF)
5.2.4 Non-CF Bronchiectasis(NCFB)
5.2.5 Other
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Genetic COPD Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Genetic COPD Market Size Forecast by Applications
6.2.1 Hospitals
6.2.2 Specialty Clinics
6.2.3 Pharmacies
6.2.4 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Genetic COPD Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Genetic COPD Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Genetic COPD Analysis and Forecast
9.1 Introduction
9.2 North America Genetic COPD Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Genetic COPD Market Size Forecast by Type
9.6.1 Global Genetic COPD Market Size Growth Rate by Indication: 2016 VS 2021 VS 2027
9.6.2 Augmentation Therapy
9.6.3 Cystic Fibrosis(CF)
9.6.4 Non-CF Bronchiectasis(NCFB)
9.6.5 Other
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Genetic COPD Market Size Forecast by Applications
9.10.1 Hospitals
9.10.2 Specialty Clinics
9.10.3 Pharmacies
9.10.4 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Genetic COPD Analysis and Forecast
10.1 Introduction
10.2 Europe Genetic COPD Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Genetic COPD Market Size Forecast by Type
10.6.1 Global Genetic COPD Market Size Growth Rate by Indication: 2016 VS 2021 VS 2027
10.6.2 Augmentation Therapy
10.6.3 Cystic Fibrosis(CF)
10.6.4 Non-CF Bronchiectasis(NCFB)
10.6.5 Other
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Genetic COPD Market Size Forecast by Applications
10.10.1 Hospitals
10.10.2 Specialty Clinics
10.10.3 Pharmacies
10.10.4 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Genetic COPD Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Genetic COPD Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Genetic COPD Market Size Forecast by Type
11.6.1 Global Genetic COPD Market Size Growth Rate by Indication: 2016 VS 2021 VS 2027
11.6.2 Augmentation Therapy
11.6.3 Cystic Fibrosis(CF)
11.6.4 Non-CF Bronchiectasis(NCFB)
11.6.5 Other
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Genetic COPD Market Size Forecast by Applications
11.10.1 Hospitals
11.10.2 Specialty Clinics
11.10.3 Pharmacies
11.10.4 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Genetic COPD Analysis and Forecast
12.1 Introduction
12.2 Latin America Genetic COPD Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Genetic COPD Market Size Forecast by Type
12.6.1 Global Genetic COPD Market Size Growth Rate by Indication: 2016 VS 2021 VS 2027
12.6.2 Augmentation Therapy
12.6.3 Cystic Fibrosis(CF)
12.6.4 Non-CF Bronchiectasis(NCFB)
12.6.5 Other
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Genetic COPD Market Size Forecast by Applications
12.10.1 Hospitals
12.10.2 Specialty Clinics
12.10.3 Pharmacies
12.10.4 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Genetic COPD Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Genetic COPD Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Genetic COPD Market Size Forecast by Type
13.6.1 Global Genetic COPD Market Size Growth Rate by Indication: 2016 VS 2021 VS 2027
13.6.2 Augmentation Therapy
13.6.3 Cystic Fibrosis(CF)
13.6.4 Non-CF Bronchiectasis(NCFB)
13.6.5 Other
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Genetic COPD Market Size Forecast by Applications
13.10.1 Hospitals
13.10.2 Specialty Clinics
13.10.3 Pharmacies
13.10.4 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Genetic COPD Market: Competitive Dashboard
14.2 Global Genetic COPD Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Pfizer
14.3.2 Baxter
14.3.3 AstraZeneca
14.3.4 Grifols
14.3.5 Teva Pharmaceutical Industries
14.3.6 Boehringer Ingelheim
14.3.7 Kamada Ltd
14.3.8 GlaxoSmithKline
14.3.9 CSL Behring
14.3.10 Takeda
14.3.11 LFB Biomedicaments
14.3.12 Abeona Therapeutics
14.3.13 Biogen
14.3.14 Vertex Pharmaceuticals
14.3.15 Baxalta
14.3.16 Arrowhead Research Corporation
14.3.17 ProBioGen
14.3.18 Chiesi Pharmaceuticals
14.3.19 Kedrion Group
14.3.20 ProMetic Life Sciences
